Fox Chase Cancer Center News

HUMMELSTOWN, PA (July 13, 2015) – Oncoceutics and Fox Chase Cancer Center have announced an agreement to conduct clinical testing with ONC201, a novel first-in-class small molecule compound being developed by the company. The study  will systematically assess dose escalation with three different schedules for oral ONC201 ranging from every three week to one week administration.

PHILADELPHIA, PA (June 24, 2015) – State Rep. Angel Cruz is inviting eligible constituents to his district office for a breast cancer screening held in coordination with the Fox Chase Cancer Center Mobile Mammography Van. Thursday, July 9, 2015.

PHILADELPHIA (June 12, 2015) — Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more difficult and sometimes impossible. Researchers at Fox Chase Cancer Center have identified a way to safely shrink the tumor, pulling it away from these vessels and allowing patients to undergo potentially curative surgery.

IRVING, TX (June 10, 2015) — Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced it has designated Fox Chase Cancer Center a center of excellence site in the Caris Centers of Excellence for Precision Medicine Network™ (Network).

PHILADELPHIA (June 8, 2015) — The Fox Chase Cancer Center–Temple University Hospital Bone Marrow Transplant (BMT) Program has recently earned the prestigious Centers of Excellence designation by OptumTM, a health services and innovation company that conducts rigorous evaluations of medical centers throughout the United States.

PHILADELPHIA (June 3, 2015) — Scientist and Nobel Laureate Irwin “Ernie” Rose, PhD, passed away June 2, 2015, after a long illness. He was 88. Rose shared the 2004 Nobel Prize for chemistry with Aaron Ciechanover and Avram Hershko of the Israel Institute of Technology for their pioneering work in discovering the ubiquitin conjugating system. Rose conducted this research as a senior scientist at Fox Chase Cancer Center in Philadelphia, where he worked from 1963 until he retired in 1995.

CHICAGO (June 1, 2015) — The goal of many cancer researchers is to find effective treatments that have few adverse effects. Researchers at Fox Chase Cancer Center in Philadelphia in collaboration with co-investigators at other centers and Merck Inc. are one step closer to finding such a treatment for urothelial cancer, for which chemotherapy is currently the standard of care.

PHILADELPHIA (June 1, 2015) — In a recent study, Fox Chase Cancer Center researchers uncovered that fee-for-service Medicare Part B physician payments made to academic otolaryngologists within a single geographic region varied significantly by institution. These inconsistencies could not be accounted for by differences in patient volumes or hospital case complexity.